Evaluation of crizotinib as radiosensitizer in sacral chordoma cells: effects of combined carbon ion particle therapy.

Birgit Lohberger, Dietmar Glänzer, Vanessa Etschmaier, Slave Trajanoski, Andreas Leithner, Beate Rinner, Dietmar Georg

Abstract read

In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Birgit LohbergerDepartment of Orthopedics and Trauma, Medical University of Graz, Graz, Austria. birgit.lohberger@medunigraz.at.ORCID http://orcid.org/0000-0002-3156-7902

Dietmar GlänzerDepartment of Orthopedics and Trauma, Medical University of Graz, Graz, Austria.

Vanessa EtschmaierDepartment of Orthopedics and Trauma, Medical University of Graz, Graz, Austria.

Slave TrajanoskiCore Facility Computational Bioanalytics, Medical University of Graz, Graz, Austria.

Andreas LeithnerDepartment of Orthopedics and Trauma, Medical University of Graz, Graz, Austria.

Beate RinnerDivision of Biomedical Research, Medical University of Graz, Graz, Austria.

Dietmar GeorgDepartment of Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chordoma resection is challenging due to proximity to the brainstem or spinal cord, and chemotherapy offers limited efficacy. Combining surgery with radiotherapy, particularly using carbon ions (C-ions) for their higher biological effectiveness, improves local control and survival rates. To investigate cellular mechanisms, two human sacral chordoma cell lines were irradiated with varying C-ions doses. Growth, cell cycle, DNA damage response, and protein phosphorylation were analyzed using flow cytometry, protein, and gene expression profiling. The potential of combining treatment with the ALK/MET inhibitor crizotinib to enhance radiosensitivity was also evaluated. C-ions irradiation resulted in a slight dose-dependent decrease in proliferation, a clear G

Indexed as

ChordomaHeavy Ion RadiotherapyPyrazolesPyridinesRadiation-Sensitizing AgentsSpinal NeoplasmsCell CycleCell Line, TumorCell ProliferationCrizotinibDNA DamageHumansProtein Kinase InhibitorsSacrumCrizotinibProtein Kinase InhibitorsPyrazolesPyridinesRadiation-Sensitizing AgentsCarbon ions irradiationCrizotinibDNA repair mechanismsSacral chordoma

Identifiers

PMID41442054

DOI10.1007/s12032-025-03172-8

PMCPMC12738640

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.